title: Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
abstract: OBJECTIVE
  The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia.
  
  
  METHODS
  Subjective experience, psychopathology, and extrapyramidal symptoms were assessed, and D(2) receptor occupancy was determined with [(123)I]iodobenzamide single photon emission computed tomography, in 22 patients whose schizophrenia was stabilized by olanzapine or risperidone.
  
  
  RESULTS
  Subjective experience, depression, and negative symptoms were related to dopamine D(2) receptor occupancy, but extrapyramidal symptoms were not.
  
  
  CONCLUSIONS
  These results provide preliminary evidence that negative subjective experience is related to high D(2) receptor occupancy. Longitudinal study is required because this relationship may have implications for dosing strategies.
authors.affiliation: Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands. ldehaan@amc.uva.nl
authors.forename: L
authors.initials: L
authors.lastname: de Haan
authors.forename: J
authors.initials: J
authors.lastname: Lavalaye
authors.forename: D
authors.initials: D
authors.lastname: Linszen
authors.forename: P M
authors.initials: PM
authors.lastname: Dingemans
authors.forename: J
authors.initials: J
authors.lastname: Booij
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000175:diagnosis; D001549:Benzamides; D001569:Benzodiazepines; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D005260:Female; D006304:Health Status; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D015899:Tomography, Emission-Computed, Single-Photon / Q000706:statistics & numerical data
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D001569:Benzodiazepines; D010890:Pirenzepine; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D018967:Risperidone; D000077152:Olanzapine